Overdosage may cause nausea, and withdrawal bleeding may occur in females. Serious ill effects have not been reported following acute ingestion of large doses of estrogen/progestin-containing oral contraceptives by young children. In the event of a possible overdosage, the system should be removed immediately and medical attention sought.

CombiPatch (estradiol, norethindrone acetate transdermal system) should not be used in women under any of the following conditions:

1. Undiagnosed abnormal genital bleeding

2. Known, suspected, or history of cancer of the breast

3. Known or suspected estrogen-dependent neoplasia

4. Active deep vein thrombosis, pulmonary embolism or history of these conditions

5. Active or recent (e.g. within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).

6. Liver dysfunction or disease.

7. CombiPatch (estradiol, norethindrone acetate transdermal system) should not be used in patients with known hypersensitivity to its ingredients.

8. Known or suspected pregnancy. There is no indication for CombiPatch (estradiol, norethindrone acetate transdermal system) in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy (see PRECAUTIONS.)

Last reviewed on RxList: 10/5/2006
This monograph has been modified to include the generic and brand name in many instances.